Company Search:
Advanced Search
Sponsored Links
Epizyme Inc Company Snapshot
Epizyme Inc operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Epizyme Inc with three other companies in this sector in the United States: Crispr Therapeutics AG (2016 sales of $5.16 million ), bluebird bio Inc ($6.16 million of which 100% was Biological Products), and Sorrento Therapeutics Incorporation ($8.15 million of which 100% was Antibody Therapeutic).

Sales Analysis. Sales increased substantially in 2016: During the year ended December of 2016, sales at Epizyme Inc were $8.01 million. This is an increase of 212.8% versus 2015, when the company's sales were $2.56 million. Despite this increase, sales are still well below the level achieved in 2014, when Epizyme Inc reported sales of $41.41 million.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Epizyme Inc
  Stock Performance Chart for Epizyme Inc
  Stock Data: Recent Stock Performance:
  Current Price (3/24/2017): 17.15
(Figures in U.S. Dollars)
1 Week 0.3%   13 Weeks 41.2%  
4 Weeks 46.0%   52 Weeks 60.0%  
Epizyme Inc Key Data:
  Ticker: EPZM Country: United States
  Exchanges: NAS Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2016 Sales 8,007,000
(Year Ending Jan 2017).
Employees: 112
  Currency: U.S. Dollars Market Cap: 998,965,651
  Fiscal Yr Ends: December Shares Outstanding: 58,248,726
  Share Type: Common Closely Held Shares: 19,252,746
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.